The is segmented on the lines of its technology, service, type, application, mild care product type and regional. Based on technology segmentation it covers CRISPR, microinjection, embryonic stem cell...
While the COVID-19 pandemic highlighted the importance of the diagnostics and research industry, the sector is expected to continue growing due to the rise in chronic diseases and AI-based innovations....
According to LabCorp (LH), Vectra and the related IP and other assets from Myriad Genetics' autoimmune business complement its prior business activity.
Stocks like Quest Diagnostics (DGX), Quidel Corporation (QDEL) and LabCorp (LH) are the right picks now, thanks to rising COVID-19 testing demand.
Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of select operating assets and intellectual property (IP) from Myriad Genetics' autoimmune...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has completed the sale of select operating assets and intellectual property (IP), including...
Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of its executive management team will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global...
Strong performance by the Clinical Solutions and Commercial Solutions segments drove Syneos Health's (SYNH) top line.
LabCorp (LH) plans to acquire the autoimmune business unit from Myriad Genetics, including Vectra, a rheumatoid arthritis assay.
Investors are optimistic about LabCorp (LH) on recovery in its base business and a raised 2021 guidance.
